Compare VSAT & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VSAT | NVCR |
|---|---|---|
| Founded | 1986 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 2.0B |
| IPO Year | 1996 | 2015 |
| Metric | VSAT | NVCR |
|---|---|---|
| Price | $77.12 | $16.59 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 6 |
| Target Price | ★ $59.80 | $28.08 |
| AVG Volume (30 Days) | ★ 1.4M | 968.8K |
| Earning Date | 05-19-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 94.42 | 21.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $655,353,000.00 |
| Revenue This Year | $5.32 | $7.72 |
| Revenue Next Year | $3.57 | $6.74 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 8.28 |
| 52 Week Low | $26.10 | $9.82 |
| 52 Week High | $93.03 | $21.45 |
| Indicator | VSAT | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 53.24 | 49.68 |
| Support Level | $66.99 | $16.33 |
| Resistance Level | $75.57 | $18.43 |
| Average True Range (ATR) | 3.78 | 0.75 |
| MACD | 0.31 | -0.07 |
| Stochastic Oscillator | 69.57 | 46.42 |
Viasat Inc an world-wide provider of communications technologies and services, focused on making connectivity accessible, available and secure for current and future customers world-wide. The company has two reportable segments: communication services and defense and advanced technologies. It generates majority of revenue from communication services segment provides a wide range of broadband and narrowband communications solutions across government and commercial mobility markets, as well as for residential and enterprise fixed broadband customers. It has presence in United States and Outside United States. The company generates majority of revenue from United States. Its products are Antennas, Terminals & radios, Modems, Semiconductors, Cybersecurity, Software & services, Home internet.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.